All patients undergoing matching had HPV testing by either p16 immunohistochemistry (IHC) or HPV in situ hybridization. IHC for p16 (G175–405; BD Pharmingen, San Diego, California) as a surrogate marker for HPB was performed as per the manufacturer’s protocol. Cases were considered positive if >80% of tumor cells showed diffuse strong cytoplasmic and nuclear positivity staining. HPV detection was performed by in situ hybridization using probes targeting a wide spectrum of HPV strains including 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, and 52 (Y1404; Dako, Carpinteria, California). Cases with punctate nuclear signal were considered positive. The majority of patients had either of the HPV testing as part of the initial diagnostic evaluation. There were 8 patients without this information. The original tissue blocks for these cases were retrieved and tested by IHC for p16. In the event of discordant HPV detection and p16 results, the p16 IHC was used to determine HPV positivity.
Y1404
Manufactured by Agilent Technologies
The Y1404 is a precision laboratory equipment manufactured by Agilent Technologies. It is designed to perform a core function within a controlled laboratory environment. The product details and specifications are available upon request.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using y1404
1
HPV Testing in Tumor Samples
2
HPV Detection Methods for Samples
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
HPV detection methods for the analyzed samples were based on the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines from the College of American Pathologists Guideline12 (link) (2018). Only samples with at least 70% nuclear and cytoplasmic expression values for p16 IHC, with a moderate to strong intensity, were considered as positive. ISH was performed in cases when the immunohistochemical analysis was discordant among the pathologists. For ISH, a wide spectrum probe (Y1404 Dako, Carpinteria, CA) was used for genotypes 6, 11, 16, 18, 31, 33, 35, 45, 51, and 52. A 16/18-specific probe (Y1412; Dako, Carpinteria, CA, USA) was also used. Sections from a carcinoma of the uterine cervix were used as positive controls.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!